FutureNeuro Header Image

Together with our industry partners, we are working to deliver faster diagnosis, personalised therapies and patient-centred care. 

We have eight industry partners, working on twelve targeted projects to benefit people with neurological diseases.


Congenica is a digital health company enabling genomic medicine with the world’s leading clinical decision support platform for the interpretation of complex genomic data.

We are working together to build new software to deliver faster and more accurate diagnoses in genetic epilepsies.


Ergo is one of the most successful IT services companies in Ireland. We are working together to enhance crucial eHealth infrastructure in Ireland and provide improved monitoring for people living with epilepsy.


Janssen is part of Johnson & Johnson Family of Companies, the world’s most comprehensive and broadly based manufacturer of healthcare products and related services. We are working together to reduce neuroinflammation in regions of the brain associated with triggering seizures.


Merck is a global healthcare company with a 125-year history of working to make a difference. We are working together to investigate cognitive impairment in people with Multiple Sclerosis using brain-monitoring technology.


Roche is the world's largest biotech company. We are working together to develop new treatments for childhood epilepsies and neuro-developmental diseases.

S3 Connected Health

S3 Connected Health is an Irish company who has been providing digital health solutions for 17 years.We are working together to co-design new healthcare technology solutions with people who have epilepsy.


UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology. We are working together to unlock the power of healthcare data to inform improvements in clinical care of people with epilepsy.

Ulysses Neuroscience

Ulysses Neuroscience Ltd. is a private research and development organisation, based in Trinity College Dublin. We are working together to explore how Fragile X Syndrome develops, aiming to gain a better understanding of its biology and identify new ways to advance treatments.


We invite partnerships with SMEs and multinational pharmaceutical and biomedical companies in sectors covering:

  • digital and biological biomarkers
  • diagnostic tools
  • therapeutic discovery and development
  • eHealth-enabled patient support platforms
  • clinical trials

Partnering opportunities with us can include research collaborations (fully- or co-funded) and joint applications for research funding (eg. H2020, NIH).

Our partners have access to:

  • integrated scientific expertise across neuroscience, clinical neurology, genetics, cell biology, materials chemistry and eHealth
  • state-of-the-art infrastructure across 5 specialist research institutions
  • national neurological clinical network and trial-ready environment
  • genetically-stratified patient population
  • favourable co-funding mechanisms
  • inherent culture of commercialisation and collaboration with industry
  • dedicated grant-writing expertise

We have in-depth experience in industry engagement, technology transfer, IP management and commercialisation. We work closely with the relevant State Agencies and can support partners to obtain appropriate state funding mechanisms.

For more information, please download our FutureNeuro Industry Brochure or to discuss a research partnership with FutureNeuro, please contact Bridget Doyle